SCHEMBL3016995

SCHEMBL3016995

Cc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cccc(F)c3)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
GFER P55789 1/20 0.47
RAB9A P51151 1/20 0.46
MAPT P10636 3/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 4/20 0.45
LMNA P02545 4/20 0.45
HTT P42858 3/20 0.45
GAA P10253 2/20 0.45
GBA1 P04062 1/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 2/20 0.45
TDP1 Q9NUW8 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013569 0.94 MAPT (0.47) KMT2AMEN1GFERRAB9AMAPT
SCHEMBL3010117 0.91 LMNA (0.45) KMT2AMEN1GFERRAB9AMAPT
SCHEMBL3023011 0.90 RAB9A (0.48) KMT2AMEN1GFERRAB9AMAPT
SCHEMBL3017462 0.89 ALDH1A1 (0.58) KMT2AMEN1MAPTUSP2RECQL
SCHEMBL3012549 0.89 GBA1 (0.45) KMT2AMEN1RAB9AMAPTUSP2
SCHEMBL3016091 0.89 TSHR (0.48) KMT2AMEN1MAPTUSP2ALDH1A1
SCHEMBL3005875 0.88 POLB (0.54) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL3017596 0.88 GFER (0.59) KMT2AMEN1GFERRAB9AMAPT
SCHEMBL3019294 0.87 TSHR (0.50) KMT2AMEN1MAPTUSP2RECQL
SCHEMBL3013350 0.87 ALDH1A1 (0.46) KMT2AMEN1RAB9AMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885GFER 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.